Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director William Aliski sold 7,500 shares of the stock in a transaction that occurred on Friday, February 19th. The shares were sold at an average price of $149.01, for a total transaction of $1,117,575.00. Following the completion of the transaction, the director now owns 73,204 shares in the company, valued at $10,908,128.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of NASDAQ RARE traded down $3.74 during mid-day trading on Tuesday, hitting $140.95. 23,296 shares of the company were exchanged, compared to its average volume of 478,201. The stock has a 50 day simple moving average of $145.83 and a 200-day simple moving average of $116.02. Ultragenyx Pharmaceutical Inc. has a 1-year low of $31.99 and a 1-year high of $179.65. The firm has a market cap of $9.44 billion, a price-to-earnings ratio of -32.96 and a beta of 2.19.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Swiss National Bank lifted its holdings in shares of Ultragenyx Pharmaceutical by 1.2% during the fourth quarter. Swiss National Bank now owns 130,152 shares of the biopharmaceutical company’s stock worth $18,017,000 after purchasing an additional 1,500 shares during the period. UBS Asset Management Americas Inc. lifted its holdings in shares of Ultragenyx Pharmaceutical by 8.7% during the third quarter. UBS Asset Management Americas Inc. now owns 65,335 shares of the biopharmaceutical company’s stock worth $5,370,000 after purchasing an additional 5,237 shares during the period. Aperio Group LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 14.3% during the third quarter. Aperio Group LLC now owns 13,553 shares of the biopharmaceutical company’s stock worth $1,114,000 after purchasing an additional 1,695 shares during the period. Great Lakes Advisors LLC acquired a new stake in shares of Ultragenyx Pharmaceutical during the fourth quarter worth $19,420,000. Finally, Wetherby Asset Management Inc. acquired a new stake in shares of Ultragenyx Pharmaceutical during the third quarter worth $390,000.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia; and Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.
Featured Story: What is a blue-chip stock?
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.